-
Nov 14, 2024 | 
modernretina.com | Dante J. Pieramici
Although intravitreal injections are a safe and effective form of drug delivery, the need for frequent injections and the corresponding disruptions to patients’ lives can pose a significant treatment burden for patients.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Anti-VEGF for RVO: The Gold Standard John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 | 
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 4Anti-VEGF for RVO: The Gold Standard Published on: October 16, 2024John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.
-
Oct 16, 2024 | 
consultantlive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
Shaping the Future of Retinal Vascular Disease Treatment - Episode 3Faricimab for DME: Durability and Patient Outcomes Published on: October 16, 2024Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for DME: Durability and Patient Outcomes Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Faricimab for nAMD: Key Trial Highlights and Case Example Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.
-
Oct 16, 2024 | 
hcplive.com | Carl D. Regillo |Margaret A. Chang |Dante J. Pieramici |John W. Kitchens
OpinionVideoOctober 16, 2024Overview of Real-World Outcomes for nAMD, DME, and RVO Patients Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.
-
Nov 6, 2023 | 
healio.com | Dante J. Pieramici |Anthony DeFino |Christine Klimanskis
You've successfully added Ophthalmology: Retina/Vitreous to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.
-
Sep 30, 2023 | 
healio.com | Dante J. Pieramici |Anthony DeFino |Christine Klimanskis
Source/Disclosures Source: Pieramici DJ. Population pharmacokinetics and safety of OPT-302, an anti-VEGF-C/-D “trap”, in patients with retinal vascular diseases. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle. Disclosures: Pieramici reports being an advisor for and having received research funding from Opthea. You've successfully added Ophthalmology: Retina/Vitreous to your alerts.
